What are the key considerations during a follow‑up visit for a patient with osteoporosis?

Follow-Up Considerations for Osteoporosis

Reassess yearly for response to therapy and fracture risk, monitoring bone mineral density every 1-2 years until stable, evaluating medication adherence, screening for secondary causes of bone loss, and adjusting treatment based on fracture occurrence or BMD decline. 1

Core Monitoring Parameters

Annual Assessment Requirements

Every patient requires yearly reassessment that includes evaluation of:

• Treatment response through BMD changes and absence of new fractures 1
• Fracture risk recalculation using current clinical status 1
• Medication adherence assessment, as regular contact with healthcare professionals improves adherence 2
• New fracture occurrence since last visit 1

Bone Mineral Density Monitoring

Obtain baseline DXA of lumbar spine and hip (plus 1/3 radius if indicated), then repeat every 1-2 years until findings are stable. 1 After stabilization, continue DXA at 1-2 year intervals or less frequently depending on clinical circumstances. 1, 2

• Use the same DXA facility and machine when possible to ensure accurate serial comparisons 1, 2
• Monitor lumbar spine, total hip, or femoral neck BMD for serial changes 1, 2
• Consider stable or increasing BMD with no new fractures as successful treatment response 2

Bone Turnover Markers (Optional)

Consider using BTMs to assess compliance and treatment efficacy. 2

• Antiresorptive therapy should reduce BTMs to at or below the median value for premenopausal women 2
• Anabolic therapy should show significant increases in BTMs indicating good response 2
• Elevated BTMs may indicate malabsorption, poor compliance, or need for parenteral therapy 2
• Note: Recent fractures transiently raise BTMs and should not be interpreted as treatment failure 2

Secondary Osteoporosis Evaluation

Re-evaluate for causes of secondary osteoporosis at each follow-up, particularly if treatment response is suboptimal. 1

Key investigations include:

• Calcium and vitamin D status - correct deficiencies identified 1
• Laboratory screening for metabolic bone diseases 3
• Medication review for drugs causing skeletal harm 1
• Assessment of conditions affecting bone metabolism 3

Lifestyle and Fall Prevention Reinforcement

Provide ongoing counseling at each visit on:

• Weight-bearing, balance, and resistance exercises 1
• Smoking cessation 1
• Fall risk reduction strategies, particularly in elderly patients 1
• Adequate calcium and vitamin D intake 2, 4
• Consider physical therapy referral to reduce discomfort, prevent falls, and improve quality of life 1

Treatment Duration and Drug Holidays

Bisphosphonate Therapy

For oral bisphosphonates: Consider a drug holiday after 5 years if fracture risk is no longer high (T-score >-2.5, fracture-free), but continue up to 10 years if fracture risk remains high. 2, 1

For zoledronate: Consider a drug holiday after 3 years in high-risk patients or after 6 years in very-high-risk patients. 2, 1

During drug holidays:

• Assess medication compliance 1
• Monitor for BMD decline beyond least significant change (LSC) 2, 1
• Monitor BTMs for rise to pretreatment values 1

Resume therapy when: 1

• A fracture occurs
• BMD declines beyond LSC
• BTMs rise to pretreatment values
• Patient meets initial treatment criteria again

Non-Bisphosphonate Antiresorptives

Drug holidays are NOT recommended for denosumab, raloxifene, or other non-bisphosphonate antiresorptives. 2, 1 Continue treatment as long as clinically appropriate. 2, 1

Critical: If denosumab is discontinued, patients MUST be transitioned to another antiresorptive to prevent rebound vertebral fractures. 1, 4

Anabolic Agents

Limit teriparatide and abaloparatide to 2 years maximum, then transition to bisphosphonate or denosumab. 2, 1

Limit romosozumab to 1 year maximum, then follow with bisphosphonate or denosumab. 2, 1

Treatment Failure Recognition

Consider treatment failure when: 2, 1

• Progression of bone loss (BMD decline beyond LSC) occurs despite therapy
• Recurrent fractures develop while on treatment
• Increasing or stable BMD with no fractures indicates adequate response 2

Management of Treatment Failure

If on oral antiresorptive: Switch to injectable antiresorptive 1

If on injectable antiresorptive: Switch to abaloparatide, romosozumab, or teriparatide 1

Reassess for: 1

• Medication compliance issues
• Secondary causes of osteoporosis
• Factors leading to suboptimal response

Specialist Referral Indications

Consider referral to endocrinologist or osteoporosis specialist when: 1

• Recurrent fractures or continued bone loss occur despite therapy without obvious treatable causes 1
• Fragility fracture with normal BMD occurs 1
• Unexpectedly low BMD or unusual features (young age, unexplained artifacts, abnormal alkaline phosphatase or phosphorus) 1
• Complicating conditions exist (decreased kidney function, hyperparathyroidism, malabsorption) 1
• Fragility fractures occur - consider fracture liaison team if available 1

Patient Education and Shared Decision-Making

Regular contact with healthcare professionals after starting treatment is one of the few interventions proven to improve adherence. 2

• Use decision aids with visual risk presentations (icon arrays, pictographs) to improve understanding of benefits and risks 2
• Discuss absolute risk reduction rather than relative risk to enhance treatment acceptance 2
• Address patient perceptions of illness and treatment at each visit 5
• Provide ongoing reinforcement of nonpharmacologic measures 6

Common Pitfalls to Avoid

• Failing to perform follow-up DXA scans - only 13% of patients receive appropriate 2-year follow-up scans in some practices 6
• Discontinuing denosumab without transition therapy - leads to rebound fractures 1, 4
• Assuming patient adherence - up to 50% of patients may not adhere to treatment recommendations despite education 7
• Overlooking secondary causes when treatment fails 1
• Continuing bisphosphonates indefinitely without reassessing need for drug holiday 2, 1, 4